Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) - Total Liabilities
Latest total liabilities as of September 2025: CN¥207.05 Million CNY
Based on the latest financial reports, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has total liabilities worth CN¥207.05 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Total Liabilities Trend (2005–2024)
This chart illustrates how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Vie Science & Technology Co Ltd
SHE:002590
|
China | CN¥2.91 Billion |
|
Shandong Oriental Ocean Sci-Tech Co Ltd
SHE:002086
|
China | CN¥324.17 Million |
|
Monro Muffler Brake Inc
NASDAQ:MNRO
|
USA | $965.03 Million |
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
USA | $194.09 Million |
|
Qingdao Eastsoft Communic Tech
SHE:300183
|
China | CN¥428.47 Million |
|
Sinclair, Inc.
F:HQ7
|
Germany | €5.29 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2024)
The table below shows the annual total liabilities of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥281.23 Million | -45.72% |
| 2023-12-31 | CN¥518.12 Million | -28.34% |
| 2022-12-31 | CN¥722.99 Million | +22.21% |
| 2021-12-31 | CN¥591.58 Million | +20.19% |
| 2020-12-31 | CN¥492.21 Million | -22.08% |
| 2019-12-31 | CN¥631.68 Million | +35.53% |
| 2018-12-31 | CN¥466.08 Million | +84.47% |
| 2017-12-31 | CN¥252.65 Million | +2.00% |
| 2016-12-31 | CN¥247.70 Million | -2.64% |
| 2015-12-31 | CN¥254.43 Million | +71.84% |
| 2014-12-31 | CN¥148.06 Million | -19.22% |
| 2013-12-31 | CN¥183.29 Million | -33.87% |
| 2012-12-31 | CN¥277.18 Million | +75.64% |
| 2011-12-31 | CN¥157.81 Million | +16.51% |
| 2010-12-31 | CN¥135.45 Million | +3.82% |
| 2009-12-31 | CN¥130.46 Million | +58.00% |
| 2008-12-31 | CN¥82.57 Million | +39.15% |
| 2007-12-31 | CN¥59.34 Million | +36.97% |
| 2006-12-31 | CN¥43.32 Million | +125.88% |
| 2005-12-31 | CN¥19.18 Million | -- |